Breast Cancer Clinical Trials in Los Angeles, California

41 studies are recruiting for breast cancer in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

   The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-c…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Los Angeles Cancer Network, Los Angeles, California

   Locations

   34 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07368998 on ClinicalTrials.gov

2. Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

   This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   6 in total

   Run by

   Regor Pharmaceuticals Inc.

   See if you can join NCT07524322 on ClinicalTrials.gov

3. A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

   The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars Sinai Medical Center, Los Angeles, California

   Locations

   53 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT07102381 on ClinicalTrials.gov

4. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

5. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

   This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Los Angeles Cancer Network, Los Angeles, California

   Locations

   210 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT05646862 on ClinicalTrials.gov

6. A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

   This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Los Angeles Cancer Network, Los Angeles, California

   Locations

   37 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07054190 on ClinicalTrials.gov

7. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

   Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Southern California, Los Angeles, California

   Locations

   11 in total

   Run by

   Nammi Therapeutics Inc

   See if you can join NCT06582017 on ClinicalTrials.gov

8. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

   The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Oncura Health - Good Samaritan, Los Angeles, California

   Locations

   433 in total

   Run by

   Pfizer

   See if you can join NCT07062965 on ClinicalTrials.gov

9. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START - Los Angeles, Los Angeles, California

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

10. Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    UCLA Hematology Oncology Santa Monica, Los Angeles, California

    Locations

    239 in total

    Run by

    Celcuity Inc

    See if you can join NCT06757634 on ClinicalTrials.gov

11. INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

    The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves incl…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California Los Angeles (UCLA), Los Angeles, California

    Locations

    3 in total

    Run by

    University of Alabama at Birmingham

    See if you can join NCT07671937 on ClinicalTrials.gov

12. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-p…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Ellison Medical Institute, Los Angeles, California

    Locations

    242 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT06790693 on ClinicalTrials.gov

13. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

14. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center, Los Angeles, California

    Locations

    243 in total

    Run by

    Relay Therapeutics, Inc.

    See if you can join NCT06982521 on ClinicalTrials.gov

15. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

    Locations

    76 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

16. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Los Angeles, California

    Locations

    20 in total

    Run by

    AstraZeneca

    See if you can join NCT05877599 on ClinicalTrials.gov

17. Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

    Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BReast CAncer gene (BRCA) carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detec…

    Stage

    Not phased

    Ages

    30 to 74

    Site

    University of California Los Angeles, Los Angeles, California

    Locations

    11 in total

    Run by

    University of California, San Francisco

    See if you can join NCT02620852 on ClinicalTrials.gov

18. A Study of Breast Cancer Risk Factors and Outcomes of People in Florida

    The purpose of this study is to understand why different people have different risks and outcomes for breast cancer and non-breast cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, Los Angeles (Specimen Analysis only), Los Angeles, California

    Locations

    3 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06780176 on ClinicalTrials.gov

19. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    USC/Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    567 in total

    Run by

    Stemline Therapeutics, Inc.

    See if you can join NCT06492616 on ClinicalTrials.gov

20. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

    AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC/Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    7 in total

    Run by

    Angiex, Inc.

    See if you can join NCT06440005 on ClinicalTrials.gov

21. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

    Stage

    Phase 3

    Ages

    18 to 60

    Site

    The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California

    Locations

    1261 in total

    Run by

    NRG Oncology

    See if you can join NCT05879926 on ClinicalTrials.gov

22. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Los Angeles Cancer Network, Los Angeles, California

    Locations

    79 in total

    Run by

    BriaCell Therapeutics Corporation

    See if you can join NCT06072612 on ClinicalTrials.gov

23. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

    This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    5 in total

    Run by

    Fate Therapeutics

    See if you can join NCT07216105 on ClinicalTrials.gov

24. FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University California, Los Angeles, Los Angeles, California

    Locations

    8 in total

    Run by

    Regor Pharmaceuticals Inc.

    See if you can join NCT05304962 on ClinicalTrials.gov

25. IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

    The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective…

    Stage

    Phase 2

    Ages

    45 and older

    Site

    Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

    Locations

    3 in total

    Run by

    Alice Chung

    See if you can join NCT06092892 on ClinicalTrials.gov